Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

52 citing papers in PubMed.

1. Differential protein expression analysis of quantitative mass spectrometry data using DEqMS.Nature protocols · 2026
   Review
2. TSC22D4 drives clear cell renal cell carcinoma progression and therapy resistance by stabilizing NRF2 through KEAP1 disruption.Cell death & disease · 2026
   Article
3. A Multi-Omics Framework Reveals Tumor Heterogeneity and Predicts Therapeutic Targets in Renal Cell Carcinoma.International journal of molecular sciences · 2026
   Article
4. Clinical Characteristics of Complex Karyotype Soft Tissue Sarcomas: A Single-Institution Cohort Study.Medicina (Kaunas, Lithuania) · 2026
   Article
5. Integrated and Comprehensive Diagnostics: An Emerging Paradigm in Precision Oncology.Cancers · 2026
   Review
6. Spatial transcriptomic profiling of metastatic renal cell carcinoma identifies chemokine-driven macrophage and CD8+ T-cell interactions predictive of immunotherapy response.Journal for immunotherapy of cancer · 2025
   Article
7. Integrative proteogenomic characterization of Wilms tumor.Nature communications · 2025
   Article
8. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.Scientific reports · 2025
   Article
9. FADS1, a lipid metabolism-related diagnostic biomarker in KIRC.Discover oncology · 2025
   Article
10. HOGA1 Suppresses Renal Cell Carcinoma Growth via Inhibiting the Wnt/β-Catenin Signalling Pathway.Journal of cellular and molecular medicine · 2025
    Article
11. Frontiers in immunology · 2025
    Article
12. Proteogenomic Analysis on RNA m6A Modification-Associated Genes Identifies a Distinct Subgroup with High IGF2BPs Expression Across Cancer Types.International journal of medical sciences · 2025
    Article
13. BAP1 complexes with YY1 and RBBP7 and its downstream targets in ccRCC cells.Open life sciences · 2025
    Article
14. Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.International journal of oncology · 2024
    Article
15. Characterization of an expanded set of assays for immunomodulatory proteins using targeted mass spectrometry.Scientific data · 2024
    Article
16. Proteomic features of soft tissue tumours in adolescents and young adults.Communications medicine · 2024
    Article
17. Integration of proteomics and transcriptomics to construct a prognostic signature of renal clear cell carcinoma.International journal of medical sciences · 2024
    Article
18. Molecular subtyping and characterization of clear cell renal cell carcinoma by tumor differentiation trajectories.iScience · 2023
    Article
19. Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.Current oncology (Toronto, Ont.) · 2023
    Review
20. Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma.Cancers · 2023
    Review

Corrections and comments

• Erratum for
  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.2019

Authors and funding

81 authors.

Funding

Abstract

PubMed holds no abstract for this paper.